Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 3
1992 1
1994 1
1997 1
2002 1
2003 3
2005 1
2007 1
2008 2
2010 1
2011 2
2013 2
2014 3
2015 4
2016 1
2018 1
2019 1
2020 3
2021 4
2022 2
2023 5
2024 4
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome.
van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, Blomkwist-Markens PH, Cornblath DR, Goedee HS, Harbo T, Jacobs BC, Kusunoki S, Lehmann HC, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Umapathi T, Topaloglu HA, Willison HJ. van Doorn PA, et al. Eur J Neurol. 2023 Dec;30(12):3646-3674. doi: 10.1111/ene.16073. Epub 2023 Oct 10. Eur J Neurol. 2023. PMID: 37814552
Guillain-Barre syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. ...The TF recommends against a second IVIg course in GBS patients with a poor prognosis; recommends against using oral corticosteroids, and weak …
Guillain-Barre syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. ...The TF r …
Chronic fatigue syndrome.
Cho WK, Stollerman GH. Cho WK, et al. Hosp Pract (Off Ed). 1992 Sep 15;27(9):221-4, 227-30, 233-6 passim. doi: 10.1080/21548331.1992.11705493. Hosp Pract (Off Ed). 1992. PMID: 1522161 Review. No abstract available.
A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist.
Wong KH, Shapiro ED, Soffer GK. Wong KH, et al. Clin Rev Allergy Immunol. 2022 Feb;62(1):264-271. doi: 10.1007/s12016-021-08906-w. Epub 2021 Oct 23. Clin Rev Allergy Immunol. 2022. PMID: 34687445 Review.
However, for a minority of patients, accompanying non-specific symptoms can persist for months following completion of therapy. The constellation of symptoms such as fatigue, cognitive dysfunction, and musculoskeletal pain that persist beyond 6 months and are associated wi …
However, for a minority of patients, accompanying non-specific symptoms can persist for months following completion of therapy. The constell …
Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.
Dalakas MC. Dalakas MC. Neurotherapeutics. 2021 Oct;18(4):2397-2418. doi: 10.1007/s13311-021-01108-4. Epub 2021 Nov 11. Neurotherapeutics. 2021. PMID: 34766257 Free PMC article. Review.
Because about 35-40% of patients on chronic therapy do not exhibit objective neurological signs of worsening after stopping IVIg but express subjective symptoms of fatigue, pains, spasms, or a feeling of generalized weakness, a conditioning effect combined wi …
Because about 35-40% of patients on chronic therapy do not exhibit objective neurological signs of worsening after stopping IVIg …
Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS).
van Doorn PA. van Doorn PA. Presse Med. 2013 Jun;42(6 Pt 2):e193-201. doi: 10.1016/j.lpm.2013.02.328. Epub 2013 Apr 28. Presse Med. 2013. PMID: 23628447 Review.
The disease is mostly preceded by an infection and generally runs a monophasic course. Both intravenous immunoglobulin (IVIg) and plasma exchange (PE) are effective in GBS. Rather surprisingly, steroids alone are ineffective. ...About 10% of GBS patients have a seco …
The disease is mostly preceded by an infection and generally runs a monophasic course. Both intravenous immunoglobulin (IVIg) …
Chronic fatigue syndrome.
Demitrack MA, Engleberg NC. Demitrack MA, et al. Curr Ther Endocrinol Metab. 1994;5:135-42. Curr Ther Endocrinol Metab. 1994. PMID: 7704698 No abstract available.
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome.
van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, Blomkwist-Markens PH, Cornblath DR, Goedee HS, Harbo T, Jacobs BC, Kusunoki S, Lehmann HC, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Umapathi T, Topaloglu HA, Willison HJ. van Doorn PA, et al. J Peripher Nerv Syst. 2023 Dec;28(4):535-563. doi: 10.1111/jns.12594. Epub 2023 Oct 10. J Peripher Nerv Syst. 2023. PMID: 37814551 Review.
Guillain-Barre syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. ...The TF recommends against a second IVIg course in GBS patients with a poor prognosis; recommends against using oral corticosteroids, and weak …
Guillain-Barre syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. ...The TF r …
IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS).
Preßler H, Machule ML, Ufer F, Bünger I, Li LY, Buchholz E, Werner C, Beraha E, Wagner F, Metz M, Burock S, Bruckert L, Franke C, Wilck N, Krüger A, Reshetnik A, Eckardt KU, Endres M, Prüss H. Preßler H, et al. Trials. 2024 Mar 7;25(1):172. doi: 10.1186/s13063-024-07982-5. Trials. 2024. PMID: 38454468 Free PMC article.
BACKGROUND: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severely debilitating condition which markedly restricts activity and function of affected people. ...METHODS: In this double-blinded, randomized, sham-controlled, exploratory trial …
BACKGROUND: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severely debilitating condition which mark …
The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated beta-Adrenergic and M3-Muscarinic Receptor Antibodies-A Pilot Study.
Oesch-Régeni B, Germann N, Hafer G, Schmid D, Arn N. Oesch-Régeni B, et al. J Clin Med. 2025 May 29;14(11):3802. doi: 10.3390/jcm14113802. J Clin Med. 2025. PMID: 40507564 Free PMC article.
Background/Objectives: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition with not fully understood causes, though evidence points to immune system involvement and possible autoimmunity. ...In seven cases, plasmapheresis ( …
Background/Objectives: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition with not …
49 results